Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Revenue of Janux Therapeutics, Inc. (JANX)
Revenue in 2023 (TTM): $8.08 M
According to Janux Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $8.08 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Janux Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $8.08 M | $6.13 M | $-71,024,000 | $-58,293,000 | $-58,293,000 |
| 2022 | $8.61 M | $7.77 M | $-66,250,000 | $-63,059,000 | $-54,154,000 |
| 2021 | $3.64 M | $3.52 M | $-32,816,000 | $-32,672,000 | $-32,559,000 |
| 2020 | $ | $-13,000 | $-4,830,000 | $-6,784,000 | $-5,255,000 |
| 2019 | $ | $-6,000 | $-3,765,000 | $-4,004,000 | $-4,237,000 |